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This study investigated the antidepressant activity of ethanolic extract of U. lanosa Wallich var. appendiculata Ridsd (ULEtOH)f o r
two-weeks administrations by using FST and TST on mice. In order to understand the probable mechanism of antidepressant-like
activity of ULEtOH in FST and TST, the researchers measured the levels of monoamines and monoamine oxidase activities in mice
brain,andcombinedtheantidepressantdrugs(ﬂuoxetine,imipramine,maprotiline,clorgyline,bupropionandketanserin).Lastly,
theresearchersanalyzedthecontentofRHYintheULEtOH.TheresultsshowedthatULEtOH exhibitedantidepressant-likeactivityin
F S Ta n dT S Ti nm i c e .U L EtOH increased the levels of 5-HT and 5-HIAA in cortex, striatum, hippocampus, and hypothalamus, the
levels of NE and MHPG in cortex and hippocampus, the level of NE in striatum, and the level of DOPAC in striatum. Two-week
injection of IMI, CLO, FLU and KET enhanced the antidepressant-like activity of ULEtOH.U L EtOH inhibited the activity of MAO-
A. The amount of RHY in ULEtOH was 17.12mg/g extract. Our ﬁndings support the view that ULEtOH exerts antidepressant-like
activity. The antidepressant-like mechanism of ULEtOH may be related to the increase in monoamines levels in the hippocampus,
cortex, striatum, and hypothalamus of mice.
1.Introduction
Depression, a widespread incapacitating psychiatric ailment,
imposes a substantial health burden on society [1]. Aﬀec-
tive disorder are characterized by a disturbance of mood
associated with alteration in behavior, energy, appetite,
sleep, and weight [2]. According to the most accepted hy-
pothesis of depression, the monoamine theory, patients
with major depression have symptoms that are reﬂected
changes in brain monoamine neurotransmitters, speciﬁcally
norepinephrine (NE) and serotonin (5-HT) [3]. Clinical
data suggests that dopamine (DA) is also involved in
the pathophysiology and treatment of depression [4]. Med-
ications such as tricyclic antidepressants (TCAs), selective
serotonin reuptake inhibitors (SSRIs), monoamine oxi-
dase inhibitors (MAOIs), speciﬁc serotonin-norepinephrine
reuptake inhibitors (SNRIs), 5-HT2 receptor antagonists,
and other heterocyclics are clinically employed for drug
therapy [5]. However, these drugs can impose a variety
of side-eﬀects including sedation, apathy, fatigue, sleep
disturbance, cognitive impairment, and sexual dysfunction,
and so forth. Hence, there remains a pressing need for new
eﬀective and better-tolerated antidepressants.
Herbal therapies may be eﬀective alternatives in the
treatment of depression, such as H y p e r i c u mp e r f o r a t u mL .
[6], Cordyceps sinensis [7], and Perilla frutescens [8]. The
Uncaria speciesrecordedinChinesePharmacopoeiaandTai-
wan Herbal Pharmacopoeia include Uncaria rhynchophylla2 Evidence-Based Complementary and Alternative Medicine
(Miquel) Jacks (abbrev. as UR), U. macrophylla Wallich. U.
hirsuta Haviland (UH), U. sinensis (Oliver) Havil, and U.
sessilifructus Roxburgh [9, 10]. According to Flora of Taiwan,
there are three diﬀerent species of Gouteng in Taiwan: UR,
UH, and U. lanosa Wallich var.a p p e n d i c u l a t aRidsd (UL)
[11]. However, UL is not recorded in Pharmacopoeia. In
traditional Chinese medicine, Gouteng is categorized as a
herb to extinguish wind, arrest convulsions, clear heat, and
pacify the liver [12]. Gouteng is mainly used to treat cardio-
vascular and central nervous system ailments, including light
headedness, convulsions, numbness, and hypertension [12].
Several studies demonstrate that the herb extract mainly acts
on neuroprotective eﬀect used to treat antiepileptic [13–15],
anti-Parkinsonian [16], anti-Alzheimer’s disease [17, 18],
anxiolytic [19], protective action against ischemia-induced
neuronaldamage[20,21],anti-inﬂammation[22].Alkaloids
are the active pharmacological component in Gouteng and
comprise components include RHY, isorhynchophylline,
hirsutine, hirsuteine, corynantheine, isocorynoxeine. RHY
exhibited a similar pharmacological activity when compared
with Gouteng [12]. RHY is an important active compo-
nent of alkaloids separated from gambir plant (Gouteng
in Chinese), RHY exerts the protective action primarily
by inhibiting of NMDA and 5-HT2 receptor-mediated
neurotoxicity during ischemia [21]. RHY also aﬀects the
levels of serotonin in cortex, striatum, hippocampus, and
hypothalamus [23, 24]. From the above perspectives, we
inferred that RHY is the key component of antidepressant-
like activity of Gouteng. Gouteng possesses neuroprotective
eﬀect, regulation of monoamine transporters, macrophage
theory [25], and regulation of glutamatergic system [26].
Our preliminary test indicated that ethanolic extract of U.
lanosa Wallich var.a p p e n d i c u l a t aRidsd. (ULEtOH) contained
thelargestamountofRHYamongUncaria speciesinTaiwan.
However, the antidepressant-like activity of ULEtOH has not
been investigated, which encouraged us to investigate the
eﬀects of ULEtOH on depression problems.
In the present study, we aimed to investigate the eﬀect
of ULEtOH in FST and TST in mice. The behavioral despair
tasks have good predictive value for antidepressant potency
inhumans[27].Moreover,weinvestigatedwhethertheeﬀect
of ULEtOH in FST and TST is dependent on its interaction
with the 5-HT, NE, and DA receptors, and the brain
monoamine neurotransmitter concentration. MAO activity
was also tested by neurochemical and biochemical assays
to conﬁrm the participation of monoamine transmitters in
treatment involving ULEtOH.
2.MaterialsandMethods
2.1. Animals. Male ICR albino mice (weighing around 22g),
purchased from BioLASCO Taiwan Co., Ltd., were used in
thepresentstudy.Theyweremaintainedat22±1◦Cwithfr ee
access to water and food, under a 12:12h light/dark cycle
(lights on at 08:00h). All manipulations were carried out
between 9:00 and 15:00h, with each animal used only once.
A l lp r o c e d u r e si nt h i ss t u d yw e r ep e r f o r m e di na c c o r d a n c e
with the NIH Guide for the Care and Use of Laboratory
Animals. The experimental protocol was approved by the
Committee on Animal Research, China Medical University.
The minimum number of animals and duration of observa-
tions required to obtain consistent data were used.
2.2. Plant Materials. Uncaria rhynchophylla (Miquel) Jacks
(UR) was collected from SiaoWulai, U. hirsuta Haviland
(UH) was collected from Wulai, and U. lanosa Wallich
var.a p p e n d i c u l a t aRidsd (UL) was collected from Xuhai,
Mudan Township of Taiwan, and was identiﬁed by Dr. Chao-
Lin Kuo, Leader of the School of Chinese Pharmaceutical
Sciences and Chinese Medicine Resources (CPCR). The
voucher specimen (Number: CMU-CPCR-UL-10001) was
deposited at CPCR.
2.3. Preparation of Plant Extract. Dried 1kg of UR, UH, and
UL, made from the stems and hooks of plants, were sliced
into small pieces and ground into a powder, and extracted
four times with 5% ammonia solution and 70% ethanol. The
extracts were ﬁltered, combined, and concentrated under
reduced pressure at 40◦C to obtain the UREtOH,U H EtOH,
ULEtOH extracts. The yield ratios of the UREtOH,U H EtOH,
ULEtOH extracts (120g, 97g, 115g) were 12%, 9.7%, 11.5%.
2.4.DrugsandDrugAdministration. ImipramineHCl(IMI),
clorgyline HCl (CLO), maprotiline HCl (MAP), ﬂuoxe-
tine HCl(FLU), bupropion HCl (BUP), ketanserin (KET),
sodium octyl sulfate, norepinephrine HCl (NE), dopamine
HCl (DA), 5-hydroxytryptamine HCl (5-HT), 4-Hydroxy-
3-methoxyphenylglycol (MHPG), 4-dihydroxyphenylacetic
acid(DOPAC), and 5-hydroxyindoleacetic acid (5-HIAA),as
well as horseradish peroxidase (HRP), benzylamine, amplex
red, and phosphate-buﬀered saline (PBS) solution were
purchased from Sigma-Aldorich (St. Louis, MO, USA). RHY
was purchased from Matsuura Yakugyo Co., Ltd (Japan).
Drugs were dissolved in normal saline, except HRP, benzy-
lamine, and amplex red that was diluted in PBS solution.
Citric acid, tri-natriumcitrate-2-hydrate, and EDTA were
purchased from Merck. UREtOH,U H EtOH,U L EtOH, or saline
wasadministeredbyoralroute,whereastheotherdrugswere
administered by i.p. route. The i.p. or p.o. administrations
were given in a volume of 10mL/kg body weight. Tests
were performed 1hr (ULEtOH) and 30min (imipramine,
ﬂuoxetine, clorgyline, maprotiline, bupropion, ketanserin)
after administration.
2.5. HPLC Analysis of UREtOH,U H EtOH,a n dU L EtOH. The
HPLC system consisted of a Shimadzu (Kyoto, Japan) LC-
10ATvp liquid chromatograph equipped with a DGU-14A
degasser, an FCV-10ALvp low-pressure gradient ﬂow control
valve, an SIL-10ADvp autoinjector, an SPD-M10Avp diode
array detector, and an SCL-10Avp system controller. Peak
areas were calculated using Shimadzu Class-LC10 software
(Version 6.12 sp5). The column was a Phenomenex Synergi
4 Fusion-RP80Acolumn(250mm ×4.6mm).Thegradient
mobile phase was methanol (solvent A) and 0.01mol/L
triethylamine, and adjusted to adjust pH to 7.5 with glacial
acetic acid (solvent B) solvent A:B = 60:40. The sample wasEvidence-Based Complementary and Alternative Medicine 3
i n j e c t e do f1 0μL. The following gradient proﬁle was run at
1.0mL/min over 60min. Peaks were detected at 274nm with
SPD-M10AVP (Shimadzu) detector. The peaks of UREtOH,
UHEtOH,a n dU L EtOH samples were identiﬁed by comparison
with the standard solutions (RHY). The UREtOH,U H EtOH,
and ULEtOH solutions were quantiﬁed by spiking with a
known amount of standard and also by comparing the area
under curve. The repeatability of the method was evaluated
by injecting the solution of UREtOH,U H EtOH,a n dU L EtOH
and standard solution three times, and the relative standard
deviation (RSD) percentage was calculated.
2.6. Behavior Despair Study. For FST and TST, animals were
divided into six groups (n = 10/group): control (0.9%
saline), the four doses of ULEtOH (0.0625, 0.125, 0.25,
0.5g/kg) and 10mg/kg IMI for 14-day treatment.
2.6.1. Forced Swimming Test (FST). The method was carried
out on mice according to the method of Porsolt et al. [28].
Mice were placed in an open cylindrical container (diameter
10cm, height 25cm), containing 15cm of water at 25±1◦C.
The duration of observed immobility was recorded during
the last 4min of the 6-minute testing period [29, 30]. Mice
are forced to swim in a restricted space from which they
cannot escape and are induced to a characteristic behavior
of immobility. Each mouse was judged to be immobile when
it ceased struggling and remained ﬂoating motionless in the
water, making only those movements necessary to keep its
head above water. Decrease in the duration of immobility
during the FST was taken as a measure of antidepressant
activity.
2.6.2. Tail Suspension Test (TST). The total duration of
immobility inducedbytailsuspensionwasmeasuredaccord-
ing to the method of Steru et al. [31]. Mice both acoustically
and visually isolated were suspended 50cm above the ﬂoor
by adhesive tape placed approximately 1cm from the tip of
the tail. The time during which mice remained immobile
was quantiﬁed during a test period of 6min. Mice were
considered immobile only when they hung passively and
completely motionless.
2.7. Open-Field Test. For open-ﬁeld test. Animals were
divided into ﬁve groups (n = 6/group): control (0.9%
saline), the three doses of ULEtOH (0.125, 0.25, 0.5g/kg), and
10mg/kg IMI for 14-day treatment.
To assess the eﬀects of ULEtOH, on locomotor activity,
micewereevaluatedintheopen-ﬁeldparadigmaspreviously
described [32]. Animals were individually placed in a box
(40 × 60 × 50cm). The mice were placed in the center
and their behavior was noted immediately and continued
for 5min. The parameters such as resting time, total move-
ment distance, total movement time, total movement were
recorded by video camera and registered in the computer.
During the interval of the test the apparatus was cleaned.
2.8. Pharmacological Treatments. We investigated whether
the antidepressant-like activity of ULEtOH in FST and TST
is dependent on its interaction with IMI (a tricyclic antide-
pressant), MAP (a selective NE reuptake inhibitor), FLU (a
selective 5-HT reuptake inhibitors), BUP (a selective DA
reuptake inhibitor), CLO (a selective MAO-A inhibitor), and
KET(apreferential5-HT2A receptorantagonist).Tothisend,
mice were pretreated with ULEtOH (0.5g/kg for two weeks’
administration)orsaline.TheyreceivedIMI,FLU,KET,CLO
(5mg/kgfortwoweeks’administration), MAP(20mg/kgfor
two weeks’ administration), or BUP (4mg/kg for two weeks’
administration) 30mins before being tested in FST and TST.
The doses of the drugs which do not aﬀect locomotor
activity and immobility time were selected on the basis of
literature data [33–35] and our preliminary test.
2.9.DeterminationofMonoaminesandTheirMetabolitesLev-
els in the Mice Frontal Cortex, Striatum, Hippocampus, and
Hypothalamus. Animals were divided into six groups (n =
6/group): control (0.9% saline), control versus FST, the
three experiment groups (0.125, 0.25, 0.5g/kg, for two
weeks’ administration), and IMI (10mg/kg for two weeks’
administration).
Monoamines were measured according to the method of
Renard et al. [36]. Brieﬂy, mice were killed by cervical dislo-
cation without anesthesia just after the FST. The brain was
removed after a rapid dissection of frontal cortex, striatum,
hippocampus, and hypothalamus were isolated. The four
brain tissues were weighed and placed separately in 5mL of
ice-cold homogenizing solution (8.8mg of ascorbic acid and
122mg of EDTA in 1000mL of perchloric acid 0.1M). After
homogenization, the solution was centrifuged at 10,000×g
for 10min at 4◦C. Twenty microliters of the resultant
supernatant was injected in the high-performance liquid
chromatography (HPLC) system. The levels of monoamines
(NE, DA and 5-HT) and their metabolites (MHPG, DOPAC,
5-HIAA) were measured by HPLC (Waters 610) with elec-
trochemical detection in the three brain tissues. The mobile
phase [4.2g/L] citric acid monohydrate, 6.8g/L sodium
acetate trihydrate, 0.8g/L octanesulfonic acid sodium salt,
0.05g/L tetrasodium ethylenediamine tetraacetate, 0.02%
(v/v) dibutyl amine, and 7% (v/v) methyl alcohol) was
delivered at 1.0mL/min. The reverse-phase column used was
a Merk Lichrospher 100RP-18 endcapped column with a
length of 12.5cm and an internal diameter of 4.0mm (E.
Merk 50734). The compounds were measured at +0.75V
using a Bioanalytical Systems LC-4C electrochemical detec-
tor.
2.10. Measurements of Monoamine Oxidase Activity. Animals
were divided into ﬁve groups (n = 6/group): control (0.9%
saline), the three doses of ULEtOH (0.125, 0.25, 0.5g/kg, for
two weeks’ administration), and CLO (10mg/kg for two
weeks’ administration).
Mice were sacriﬁced and the brain tissues was rapidly
frozen (−80◦C) until analyzed. The brain tissues was each
homogenized in 50mM phosphate buﬀer (pH 7.4) contain-
ing 0.5mM EDTA and 0.25M sucrose and stored at −80◦C.
Protein content of the homogenate was determined using
the method of Lowry et al. [37]. Mouse brain monoamine4 Evidence-Based Complementary and Alternative Medicine
oxidase activity was measured following the method of Zhou
and Panchuk-Voloshina [38]. Brieﬂy, For the measurement
of each type of MAO, serotonin was used as a substrate
for MAO-A and benzylamine for MAO-B. The experiments
were conducted at room temperature for 60min in a
reaction mixture with brain homogenates at a ﬁnal protein
concentration of 8mg/mL. For the sensitivity assay, the brain
homogenates with diﬀerent protein concentrations were
incubated in a reaction mixture of 200mM Amplex Red,
1mM benzylamine, and 1U/mL HRP at room temperature
for 60min.
2.11. Statistical Analysis. All results are expressed as mean ±
SEM. Data were analyzed by one-way ANOVA followed by
Bonferroni,s multiple range test. The criterion for statistical
signiﬁcance was P<0.05. All statistical analyses were carried
out by using SPSS for Windows (SPSS Inc.).
3. Results
3.1. HPLC Analysis of UREtOH,U H EtOH,a n dU L EtOH. The
HPLC chromatogram shows that RHY is the major com-
ponents among organic molecules of UREtOH,U H EtOH,a n d
ULEtOH. As shown in Figure 1, the content of RHY in UREtOH
and ULEtOH were 3.87mg/g and 17.12mg/g. UHEtOH did not
detect the content of RHY.
3.2. Eﬀect of Repeated Treatment with ULEtOH on the Immo-
bility Time Both in the FST and TST. In order to investigate
whether ULEtOH can produce chronic changes in depression-
r e l a t e db e h a v i o ri nF S Ta n dT S T ,w et r e a t e dm i c ew i t h
diﬀerent dosages to mice via continuous oral administration
for 14 days. ULEtOH decreased signiﬁcantly the immobility
time in FST (dose range: 0.0625–0.5g/kg, p.o.; Figure 2).
ULEtOH also caused a reduction in the immobility time in
TST (dose range: 0.0625–0.5g/kg, p.o.; Figure 3). In both
tests, IMI at doses of 10mg/kg produced a reduction of the
immobility time that was stronger than that aﬀorded by
ULEtOH (Figure 3).
3.3. Eﬀect of Repeated Treatment with ULEtOH on the
Locomotor Activity in Mice. In order to determine whether
ULEtOH actually possesses an antidepressant-like activity, we
tested the locomotion counts to exclude the excitatory or
inhibitory eﬀects after administration of ULEtOH.U L EtOH
did not aﬀect locomotor activity at the same doses that
signiﬁcantly reduced immobility response in the FST and
TST (Figure 4).
3.4. Eﬀect of Combination of ULEtOH with IMI, FLU, CLO,
M A P ,B U P ,a n dK E To nI m m o b i l i t yP e r i o d si nF S Ta n dT S T .
The results depicted in Figure 5 show the eﬀect of treatment
of mice with IMI (5mg/kg for two weeks’ administration,
a dose that did not aﬀect the immobility time) on the
reduction in immobility time elicited by ULEtOH (0.5g/kg,
p.o.). Post-hoc analyses indicated that the treatment of
mice with IMI augmented the antidepressant-like activity of
ULEtOH in FST and TST.
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Figure 1: The HPLC chromatographic proﬁles, at 274nm, of (a)
UREtOH,( b )U H EtOH, and (c) ULEtOH.
The results depicted in Figure 6 show the eﬀect of
treatment of mice with FLU (5mg/kg for two weeks’
administration, a dose that did not aﬀect the immobility
time) on the reduction in immobility time elicited by
ULEtOH (0.5g/kg, p.o.). Post-hoc analyses indicated that the
treatment of mice with FLU augmented the antidepressant-
like activity of ULEtOH in FST and TST.
The results depicted in Figure 7 show the eﬀect of
treatment of mice with CLO (5mg/kg for two weeks’
administration, a dose that did not aﬀect the immobility
time) on the reduction in immobility time elicited by
ULEtOH (0.5g/kg, p.o.). Post-hoc analyses indicated that the
treatment of mice with CLO augmented the antidepressant-
like activity of ULEtOH in FST and TST.
The results depicted in Figure 8 show the eﬀect of
treatment of mice with MAP (20mg/kg, for two weeks’
administration, a dose that did not aﬀect the immobility
time) on the reduction in immobility time elicited by
ULEtOH (0.5g/kg, p.o.). Post-hoc analyses indicated that
the treatment of mice with MAP did not augment the
antidepressant-like activity of ULEtOH in FST and TST.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: The eﬀect of ethanol extracts from U. lanosa (ULEtOH,
0.0625–0.5g/kg, p.o.), or Imipramine (IMI, 10mg/kg, i.p.) for
two weeks’ administration on the immobility time in the forced
swimming task. The values are mean ± SEM for each group (n =
10). ∗∗P<0.01, ∗∗∗P<0.001 as compared with control group
(one-way ANOVA followed by Bonferroni’s multiple range test).
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Figure 3: The eﬀect of ethanol extracts from (ULEtOH, 0.0625–
0.5g/kg, p.o.), or Imipramine(IMI, 10mg/kg, i.p.) for two weeks’
administration on the immobility time in the tail suspension test.
The value are mean ± SEM for each group (n = 10). ∗∗∗P<0.001
as compared with control group (one-way ANOVA followed by
Bonferroni’s multiple range test).
The results depicted in Figure 9 show the eﬀect of treat-
ment of mice with BUP (4mg/kg, for two weeks’ administra-
tion, a dose that did not aﬀect the immobility time) on the
reduction in immobility time elicited by ULEtOH (0.5g/kg,
p.o.). Post-hoc analyses indicated that the treatment of mice
with BUP did not augment the antidepressant-like activity of
ULEtOH in FST and TST.
The results depicted in Figure 10 show the eﬀect of
treatment of mice with KET (5mg/kg for two weeks’
administration, a dose that did not aﬀect the immobility
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Figure 4: The eﬀects of ULEtOH for two weeks administration on
resting time, total movement distance and total movement time in
the locomotor. The value are mean ± SEM for each group (n = 6).6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀe c to fi m i p r a m i n e ( I M I ) o nU L EtOH -induced immobil-
ity time in (a) FST and (b) TST. The value are mean ± SEM for each
group (n = 6). ∗∗∗P<0.001 as compared with ULEtOH alone.
time) on the reduction in immobility time elicited by
ULEtOH (0.5g/kg, p.o.). Post-hoc analyses indicated that the
treatment of mice with KET augmented the antidepressant-
like activity of ULEtOH in FST and TST.
3.5.DeterminationofMonoaminesandTheirMetabolitesLev-
els in the Mice Frontal Cortex, Striatum, Hippocampus, and
Hypothalamus. The concentrations of NE, DA, 5-HT, and
its metabolites in the frontal cortex, striatum, hippocampus,
and hypothalamus are presented in Tables 1, 2, 3,a n d
4.U L EtOH (0.125g/kg, p.o.) increased the level of NE in
hypothalamus, and the level of DOPAC in striatum. ULEtOH
(0.25g/kg, p.o.) increased the level of 5-HT in cortex and
striatum, the level of 5-HIAA in striatum, hippocampus, and
hypothalamus, and the level of NE in cortex, hippocampus,
the level of MHPG in hippocampus,and level of DOPAC
in striatum. ULEtOH (0.5g/kg, p.o.) increased the levels
of 5-HT and 5-HIAA in cortex, striatum, hippocampus,
and hypothalamus, the levels of NE and MHPG in cortex
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Figure 6: Eﬀect of ﬂuoxetine (FLU)on ULEtOH-induced immobility
time in (a) FST and (b) TST. The value are mean ± SEM for each
group (n = 6). ∗∗P<0.01 as compared with ULEtOH alone.
and hippocampus, the level of NE in striatum, and level
of DOPAC in striatum.
3.6. Measurements of Monoamine Oxidase Activity. Table 5
summarizes the eﬀect of ULEtOH and clorgyline on the
activities of type A and type B monoamine oxidase in mouse
brain. ULEtOH (0.5g/kg) and clorgyline (10mg/kg) inhibited
the activity of type A monoamine oxidase in the mouse
brain.
4. Discussion
Inthepresentstudy,weanalyzedtheRHYcontentofGouteng
g r o w ni nT a i w a na n dc h o o s et h eUL which has higher
amount of RHY as the research sample. To raise the yield
ratio of alkaloid, the researcher alkalized the three species
of Gouteng by 5% ammonia solution, turning alkaloid salts
into free alkaloid, followed by 70% ethanol extracting. After
the above procedure, the UREtOH,U H EtOH,a n dU L EtOH were
produced. Afterwards, the researcher used HPLC methodEvidence-Based Complementary and Alternative Medicine 7
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Figure 7: Eﬀect of clorgyline (CLO)on ULEtOH-induced immobility
time in (a) FST and (b) TST. The value are mean ± SEM for each
group (n = 6). ∗∗P<0.01∗∗∗P<0.001 as compared with ULEtOH
alone.
to analyse the RHY content of the samples. The analytical
result of ULEtOH contained most RHY among all. However,
from the study of Jung et al. [19], the aqueous extract
of UR (URDDW) possesses anxiolytic activity by inhibiting
WAY1005635 (the compounds that could selective block
5-HT1A presynaptic receptors and prevent the negative
feedbackmightbeeﬀective)[34].Inthisstudy,theresearcher
analysed the RHY content of URDDW. Result showed that
URDDW did not detect RHY (unpublished data) and sug-
gested that the antianxiety activity of URDDW was not related
to RHY.
The forced swimming and tail suspension tests are
behavioral despair tests useful for probing the pathological
mechanism of depression and for the evaluation of antide-
pressant drugs [39]. These tests are sensitive to all major
classes of antidepressant drugs including tricyclics, serotonin
reuptake inhibitors, monoamine oxidase inhibitors, and
atypical [28]. Characteristic behavior scored in both tests is
termed immobility, reﬂecting behavioral despair as seen in
human depression [31]. The results presented here show, to
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Figure 8: Eﬀect of maprotiline (MAP) on ULEtOH-induced immo-
bility time in (a) FST and (b) TST. The value are mean ± SEM for
each group (n = 6). N.S.: nonsigniﬁcant.
our knowledge for the ﬁrst time, that ULEtOH given orally is
eﬀective in producing signiﬁcant antidepressant-like activity,
when assessed in FST and in TST. The antidepressant-like
activity of ULEtOH in FST and TST was not comparable but
weaker than that of IMI, used as a standard antidepressant in
ad o s eo f1 0m g / k g .
In FST and TST, psychostimulants are also shown to
reduce immobility but in contrast to antidepressants they
cause a marked motor stimulation. Locomotor activity test
was also observed after ULEtOH treatment. We employed
an additional locomotor activity test to check the motor
stimulating activity of ULEtOH after tests. These results
suggested that ULEtOH, at the same doses that produce
an antidepressant-like activity, did not show signiﬁcant
locomotor stimulation. The antidepressant-like activity of
ULEtOH is speciﬁc.
The precise mechanisms by which ULEtOH produced
antidepressant-like activity are not completely understood.
However, according to our results, the antidepressant-like
activity of ULEtOH was additive to the treatment of animals8 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Eﬀect of bupropion(BUP)on ULEtOH-induced immobil-
ity time in (a) FST and (b) TST. The value are mean ± SEM for each
group(n = 6). N.S.: nonsigniﬁcant.
withIMI(a-NE/5-HTreuptakeinhibitor),FLU(aselective5-
HT reuptake inhibitor), CLO (a selective MAO-A inhibitor),
and KET (a preferential 5-HT2A receptor antagonist) when
tested in FST and TST. This eﬀect was not accompanied
by hyperlocomotion (data not shown) that could produce
a false-positive antidepressant-like activity. These suggest
that ULEtOH might produce antidepressant-like activity by
interaction with monoamines receptors, and monoamine
oxidase, thereby increasing the levels NE, 5-HT, and DA in
the brains of mice and was related to downregulation of
5-HT2A receptor (inhibition of 5-HT2A receptor expression
exerts antidepressant-like activity) [40]. Moreover, this study
suggests that the combination of ULEtOH with these antide-
pressants might be helpful in the treatment of depression.
Intensive research into the neurobiology of depression
suggests that an increase in the monoamine levels at the
synapse is believed to be the ﬁrst step in a complex
cascade of events that results in antidepressant activity [41].
Four brain regions were studied: the frontal cortex, the
striatum, the hippocampus, and the hypothalamus, which
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Figure 10: Eﬀe c to fk e t a n s e r i n( K E T )o nU L EtOH-induced immo-
bility time in (a) FST and (b) TST. The value are mean ± SEM for
each group(n = 6). ∗P<0.05 as compared with ULEtOH alone.
are involved Integrating in important behavioral functions,
such as emotion, motivation, and learning and memory
[41, 42]. Abnormal monoamine levels in four brain regions
may be relevant to the depressed state. Our results show that
ULEtOH increased the levels of 5-HT and 5-HIAA in cortex,
striatum, hippocampus, and hypothalamus, the levels of NE
and MHPG in cortex and hippocampus, the level of NE in
striatum, and the level of DOPAC in striatum. The HPLC
assay showed that a signiﬁcant increase in DOPAC in the
striatum was observed after ULEtOH treatment. The results
from behavior and HPLC assay were inconsistent possibly
because behavioral changes are not signiﬁcantly sensitive to
small changes in dopamine level in the brain. Integrating
the HPLC, and pharmacological treatments results, we
inferred that the anti-depression mechanism of ULEtOH
might be partly due to its inﬂuence on the function of 5-
HT,NE systems through the regulation of serotonergic and
adrenergicreceptorsand/orthemetabolismof5-HTandNE.Evidence-Based Complementary and Alternative Medicine 9
Table 1: Eﬀect of ULEtOH on the concentration (ng/g tissue) of monoamines and their metabolites in the cortex of mice brain.
Groups
Cortex (ng/g tissue)
NE MHPG DA DOPAC 5-HT 5-HIAA
Normal 525.96 ±43.71 280.41 ±12.76 735.26±53.40 625.26±63.78 438.75 ±36.89 372.32 ±18.22
Control versus FST 168.49±17.15### 119.06 ±13.32# 596.01±27.13 530.69±49.32 216.67 ±25.11## 143.76±31.54###
Imipramine 10mg/kg 583.92±28.9∗∗∗ 233.37 ±59.00 701.97±56.63 411.47±49.71 711.42 ±63.27∗∗∗ 342.13±18.26∗∗
ULEtOH 0.125g/kg 146.39 ±10.11 176.81 ±29.29 834.17±55.66 395.71±26.67 346.30 ±8.91 167.40 ±31.30
ULEtOH 0.25g/kg 292.78 ±26.93∗ 145.86 ±18.35 695.69±29.25 433.10±16.43 499.49 ±19.78∗∗∗ 165.02 ±46.22
ULEtOH 0.5g/kg 320.69±20.16∗∗ 273.19 ±58.11∗ 622.98±67.15 577.92±88.01 639.27 ±49.86∗∗∗ 311.63±23.23∗∗
Values were the mean ± SEM (n = 6). #P<0.05, ##P<0.01, ###P<0.001 as compared with the normal group. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 as
compared with the control versus FST group (one-way ANOVA following by Bonferroni’s test).
Table 2: Eﬀe c to fU L EtOH on the concentration (ng/g tissue) of monoamines and their metabolites in the striatum of mice brain.
Groups
Striatum (ng/g tissue)
NE MHPG DA DOPAC 5-HT 5-HIAA
Normal 408.22 ±74.25 80.23 ±84.83 1021.35 ±74.58 1256.23 ±160.42 334.60 ±65.88 242.45 ±21.90
Control versus FST 331.74 ±33.07 75.23 ±45.83 681.62 ±69.78 927.96 ± 198.73 103.09 ±44.16# 140.02 ±50.36
Imipramine 10mg/kg 696.74 ±83.8∗∗ 78.71 ±17.44 950.93 ±58.4 1032.17 ±160.68 426.01 ±60.75∗ 352.37 ±87.32
ULEtOH 0.125g/kg 466.40 ±33.77 61.58 ±7.65 835.30 ±92.92 1864.85±272.97∗ 241.71 ±29.87 254.62 ±36.12
ULEtOH 0.25g/kg 467.62 ±24.12 110.10 ±38.63 735.40 ±61.14 1873.61±189.68∗ 356.64 ±73.28∗ 508.37±43.27∗∗∗
ULEtOH 0.5g/kg 860.02±67.30∗∗∗ 129.91 ±16.13 743.81 ±86.79 1847.19±182.61∗ 420.20 ±94.71∗ 751.38±34.33∗∗∗
V a l u ew e r et h em e a n± SEM (n = 6). #P<0.05 as compared with the normal group. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 as compared with the control
group (one-way ANOVA following by Bonferroni’s test).
Table 3: Eﬀect of ULEtOH on the concentration (ng/g tissue) of monoamines and their metabolites in the hippocampus of mice brain.
Groups
Hippocampus (ng/g tissue)
NE MHPG DA DOPAC 5-HT 5-HIAA
Normal 581.57 ±25.89 640.84 ± 44.27 713.98 ±27.06 639.43 ±49.15 638.07 ±31.74 613.67 ±78.51
Control versus FST 183.67 ±24.01# 210.34 ±22.72## 275.21 ±34.86## 268.46 ±26.14 113.72 ±25.71### 192.77 ±15.70##
Imipramine 10mg/kg 851.76±96.22∗∗∗ 682.1±31.39∗∗∗ 633.56 ±63.63 445.35 ±94.67 898.71 ±35.47∗∗∗ 1028.46±75.43∗∗∗
ULEtOH 0.125g/kg 431.38 ±52.01 386.16 ± 27.86 435.43 ±63.16 360.87±107.15 201.48 ±73.29 354.73 ±91.78
ULEtOH 0.25g/kg 510.95 ±52.67∗∗ 515.38±97.48∗∗ 539.59 ±72.49 432.42 ±67.79 229.74 ±55.82 509.97 ±44.55∗
ULEtOH 0.5g/kg 824.21±71.69∗∗∗ 735.31 ±.84∗∗∗ 612.29 ±84.59 532.09 ±42.28 381.89 ±10.25∗∗ 665.73 ±42.55∗∗
Value were the mean ± SEM (n = 6). #P<0.05, ##P<0.01, ###P<0.001 as compared with the normal group.
∗P<0.05,∗∗P<0.01,∗∗∗P<0.001 as compared with the control group (one-way ANOVA following by Bonferroni’s test).
Table 4: Eﬀe c to fU L EtOH on the concentration(ng/g tissue)of monoamines and their metabolites in the hypothalamus of mice brain.
Groups
Hypothalamus (ng/g tissue)
NE MHPG DA DOPAC 5-HT 5-HIAA
Normal 162.87 ±18.84 359.47 ± 42.85 673.24 ±39.45 632.91±31.21 82.70 ±1.59 610.04 ±52.00
Control versus FST 82.12 ±10.34# 301.73 ± 33.83 368.95 ± 24.42## 359.99±20.43 27.61 ±4.24### 250.69 ±51.46##
Imipramine 10mg/kg 491.34±17.78∗∗ 750.59±67.95∗∗ 466.00 ±49.59 498.45±12.95 72.86 ±5.06∗∗∗ 780.53±78.00∗∗∗
ULEtOH 0.125g/kg 86.59 ±20.24 256.23 ± 28.26 311.62 ±49.34 344.75±46.98 37.00 ±6.16 612.67 ±65.72∗∗
ULEtOH 0.25g/kg 161.51 ±11.41 357.50 ± 22.94 407.61 ±23.02 564.04±42.35 40.99 ±3.46 633.35 ±65.61∗∗
ULEtOH 0. 5g/kg 148.62 ±13.21 501.39 ± 57.27 439.88 ±51.01 585.68±26.87 86.84 ±11.23∗∗∗ 877.39±75.70∗∗∗
Value were the means ± SEM (n = 6). #P<0.05, ##P<0.01, ###P<0.001 as compared with the Normal group.
∗∗P<0.01, ∗∗∗P<0.001 as compared with the control group (one-way ANOVA following by Bonferroni’s test).10 Evidence-Based Complementary and Alternative Medicine
Table 5:EﬀectsofULEtOH (0.125,0.25,0.5g/kg,p.o.)andclorgyline
(10mg/kg, i.p.) for two weeks’ administration on MAO-A, MAO-B
activity in mouse brain.
Group MAO-A activity (%
of mouse brain)
MAO-B activity (%
of mouse brain)
Control 98.56 ±4.44 96.89 ±4.10
Clorgyline 10mg/kg 45.05 ±8.02∗∗ 102.41 ±5.50
ULEtOH 0.125g/kg 107.31 ±14.21 103.86 ±7.46
ULEtOH 0.25g/kg 80.97 ±7.20 107.70 ±5.50
ULEtOH 0.5g/kg 49.84 ±7.02∗∗ 105.94 ±3.99
V a l u ew e r et h em e a n± SEM (n = 6). ∗∗P<0.01 as compared with the
control group (one-way ANOVA following by Bonferroni’s test).
MAO exists in two subtypes, A and B. The original
MAOIs are nonselective, inhibiting both forms. The A
form of MAO preferentially metabolizes 5-HT and NE, the
monoamines most closely linked to depression. The B form
preferentially metabolizes trace amines, including phenethy-
lamine. MAO-A and MAO-B metabolize DA and tyramine
[43]. Hou et al. [44] concluded that the (+) catechin and
(−) epicatechin of methanol extract of UR had inhibitory
eﬀect on MAO-B activity. However, due to the diﬀerent
extracting methods in this research, we did not detect the
contents of (+) catechin and (−)e p i c a t e c h i ni nU L EtOH.
(unpublished data). Furthermore, based on the same studies
have reported a positive correlation between oxidative stress
and depression [45], and Gouteng has antioxidant activity
[46]. We applied two-weeks oral administration of ULEtOH
to conduct monoamine oxidase activity test. The results of
our study reveal that ULEtOH inhibited MAO-A activity.
Severalstudiesdemonstratedthattheherbextractandits
activecomponentRHYprotectneuronsagainsttheischemia,
glutamate-, or dopamine-induced damage or death [20, 21,
47], and regulation of monoamine transporters [23, 24].
From the above studies, we inferred that RHY might be the
main active component in Gouteng’s antidepression activity.
Further studies are needed to verify the antidepressant
activity of RHY and underlying mechanisms.
In conclusion, ULEtOH contained most RHY among
Uncaria species of Gouteng in Taiwan. ULEtOH showed
antidepressant-like activity in FST and TST. The mechanism
of anti-depressive-like activity of ULEtOH was mediated by
increasing the monoamines level, particularly 5-HT and NE
in diﬀerent brain regions of mice. Furthermore, ULEtOH
was proofed to inhibit the activity of MAOA. From the
pr esentstud y ,w ec oncludethatUL EtOH isaworthdeveloping
Taiwanese speciﬁc medicinal plant, and thus we suggest that
it should be included in Pharmacopoeia.
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